Conclusion of MOU with Airlangga University Hospital ~ Effort to accomplish the 100 Days mission in the area of Infectious Disease ~

Remedy & Company Corporation (Located in Chiyoda-ku, Tokyo; President and CEO: Masakuni Ukita, hereinafter referred to as “We” ) have concluded a Memorandum of Understanding (MOU) with Airlangga University Hospital, a public university in Indonesia, with respect to the promotion of clinical trials on infectious diseases, and the introduction of Controlled Human Infection Model (CHIM) studies to Indonesia.

Due to Airlangga University Hospital’s extensive experience and knowledge in the research and treatment of Neglected Tropical Diseases (NTDs), collaborating with them would mean while we bring CHIM studies into the country, we can also help develop concrete actions to further bolster their clinical trial ability in areas of infectious diseases such as NTDs, tuberculosis and malaria.

Moreover, we believe that given our experience in trial conduction in South Global countries ranging from Southeast Asia to South Asia, South America and Africa, through such collaboration, Remedy & Company will enlighten the world about CHIM study and its high ethical standards, and in the process realize a systematic approach for rapid development of safe and effective vaccines and treatments for infectious diseases, achieving our 100 Days mission.